Pancreatic neuroendocrine tumor
Also known as islet cell tumor, islet cell tumors - pancreas, islet cell tumors of the pancreas, islet cell tumour+15 more
islet cell tumor, islet cell tumors - pancreas, islet cell tumors of the pancreas, islet cell tumour, islet cell tumours - pancreas, islet cell tumours of the pancreas, pancreatic NET, well differentiated pancreatic endocrine neoplasm, well differentiated pancreatic endocrine tumor, well differentiated pancreatic endocrine tumour, well-differentiated NEN of pancreas, well-differentiated neuroendocrine neoplasm of pancreas, well-differentiated pancreatic NEN, well-differentiated pancreatic neuroendocrine neoplasm, PANET, neuroendocrine tumor of pancreas, neuroendocrine tumour of pancreas, pancreatic endocrine tumor, pancreatic endocrine tumour.
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q2 2027.
- Q2 2027Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Q1 2028Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
- Q2 2029A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
- Q4 2029A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations
Clinical MilestonesViewHide
- 2026-09-10A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine TumorsResults expected Q2 2029
- 2026-09-03A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic AlterationsResults expected Q4 2029
- 2026-09-02Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine TumorsResults expected Q1 2028
- 2026-06-24Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsResults expected Q2 2027
- 2026-09-10ClinicalA Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine TumorsResults expected Q2 2029
- 2026-09-03ClinicalA Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic AlterationsResults expected Q4 2029
- 2026-09-02ClinicalPhase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine TumorsResults expected Q1 2028
- 2026-08-04ClinicalRandomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)Results posted
- 2026-06-24ClinicalSurgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine TumorsResults expected Q2 2027
- 2026-06-09ClinicalA Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine TumorsTerminated
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Conditional marketing authorisation — Renal cell carcinoma (RCC) Welireg is indicated as monotherapy for the treatment of adul… (2025)
Generic approval — Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of… (2021)
Original application approval — Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell… (2016)
Original application approval — Hormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment… (2009)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
islet cell tumor, islet cell tumors - pancreas, islet cell tumors of the pancreas, islet cell tumour, islet cell tumours - pancreas, islet cell tumours of the pancreas, pancreatic NET, well differentiated pancreatic endocrine neoplasm, well differentiated pancreatic endocrine tumor, well differentiated pancreatic endocrine tumour, well-differentiated NEN of pancreas, well-differentiated neuroendocrine neoplasm of pancreas, well-differentiated pancreatic NEN, well-differentiated pancreatic neuroendocrine neoplasm, PANET, neuroendocrine tumor of pancreas, neuroendocrine tumour of pancreas, pancreatic endocrine tumor, pancreatic endocrine tumour
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.